Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 7/20 | 0.74 |
| ▸ | MGAM | O43451 | 5/20 | 0.74 |
| ▸ | GLA | P06280 | 3/20 | 0.74 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | AGL | P35573 | 2/20 | 0.68 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.68 |
| ▸ | GBA1 | P04062 | 1/20 | 0.68 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nojirimycin SCHEMBL24518012 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL18819521 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL11239684 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL25084034 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| Nojirimycin SCHEMBL20470306 | 1.00 | FUCA1 (0.74) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL7824407 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL7811568 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL2265531 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL18271004 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA | |
| SCHEMBL1879685 | 0.85 | MGAM (1.00) | FUCA1MGAMGLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137203-A1 | GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY | ABBOTT DIABETES CARE, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250194964-A1 | GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY | ABBOTT DIABETES CARE, INC. | 2025-06-19 | — | — | US | claimed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-115838350-B | Method for simultaneously preparing deoxynojirimycin, chlorogenic acid and morin from cortex mori | 陕西嘉禾药业有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-118202061-A | Method of treating fabry disease using viral vector constructs | 桑格摩生物治疗股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116926030-A | Transaminase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2023-10-24 | — | — | CN | claimed |
| CN-116710185-A | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | 阿米库斯治疗学公司 | 2023-09-05 | — | — | CN | claimed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-4908439-A | Synthesis of intermediate useful in the preparation of nojirimycin and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | claimed |
| EP-0344383-A1 | Novel alpha-Glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | claimed |
| EP-0345104-A2 | Novel Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | claimed |
| EP-0319986-A2 | Fibrinolytic agents | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-06-14 | — | — | EP | claimed |
| EP-0189461-A4 | METHOD OF DETERMINING CYSTIC FIBROSIS CILIOSTATIC FACTOR. | COOPERBIOMEDICAL INC (US) | 1988-05-10 | — | — | EP | claimed |
| US-4673633-A | Method of determining cystic fibrosis ciliostatic factor | COOPERBIOMEDICAL, INC. (US) | 1987-06-16 | — | — | US | claimed |
| EP-0189461-A1 | METHOD OF DETERMINING CYSTIC FIBROSIS CILIOSTATIC FACTOR. | COOPERBIOMEDICAL INC (US) | 1986-08-06 | — | — | EP | claimed |
| WO-1986000343-A1 | METHOD OF DETERMINING CYSTIC FIBROSIS CILIOSTATIC FACTOR | COOPERBIOMEDICAL, INC. (US) | 1986-01-16 | — | — | WO | claimed |
| US-4339585-A | Method for the production of 2-hydroxymethyl-3,4,5-trihydroxy piperidine and the corresponding N-methyl derivative | NIPPON SHINYAKU CO., LTD. (JP) | 1982-07-13 | — | — | US | claimed |
| US-4064277-A | SOYBEAN MILK, BETA-GLYCOSIDASE | KIKKOMAN SHOYU CO., LTD. (JA) | 1977-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | FUCA1 31/4885MGAM 73/4885GLA 98/4885 |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | GALE, UGGT1, DERA | FUCA1 8/4885MGAM 43/4885GLA 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.